# Swedish Orphan Biovitrum

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/swedishorphanbiovitrum).

## Overview

Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases. The company focuses on providing innovative medicines in haematology, immunology, and specialty care. With approximately 1,800 employees, Sobi operates across Europe, North America, the Middle East, Asia, and Australia. In 2024, Sobi reported a revenue of SEK 26 billion and is publicly traded on Nasdaq Stockholm under the ticker STO:SOBI.

## Products & services

• Elocta® for haemophilia A
• Altuvoct for haemophilia
• Doptelet for thrombocytopenia
• Aspaveli/Empaveli for paroxysmal nocturnal hemoglobinuria
• Vonjo for myelofibrosis
• Specialty care medicines

- **Haematology** (63%) — Includes treatments for haemophilia and related conditions
- **Immunology** (32%) — Comprises medicines for immune system disorders
- **Specialty Care** (5%) — Focuses on rare diseases and niche therapeutic areas

- Elocta® for haemophilia A
- Altuvoct for haemophilia
- Doptelet for thrombocytopenia
- Aspaveli/Empaveli for paroxysmal nocturnal hemoglobinuria
- Vonjo for myelofibrosis
- Specialty care medicines

## Customers

Sobi serves a diverse range of customers, primarily focusing on healthcare providers and institutions that treat rare and debilitating diseases. The company's products are used by hospitals, specialized clinics, and healthcare professionals who manage patients with complex medical conditions. Sobi's customer base is global, with significant presence in Europe, North America, and emerging markets. The company aims to provide reliable access to innovative therapies, addressing unmet medical needs and improving patient outcomes.

- **Healthcare Providers** (primary) — Hospitals and clinics purchasing treatments for rare diseases
- **Specialized Clinics** (secondary) — Focused on haemophilia and immunology treatments
- **Emerging Markets** (emerging) — Growing demand for innovative therapies

- Hospitals treating rare diseases
- Specialized clinics for haemophilia and immunology
- Healthcare professionals managing complex conditions
- Global presence with focus on Europe and North America
- Institutions seeking innovative therapies for rare conditions

## Geography

Sobi operates globally, with a strong presence in Europe, North America, and expanding markets in the Middle East, Asia, and Australia. The company's headquarters are located in Stockholm, Sweden. Sobi's geographic reach allows it to address diverse healthcare needs and regulatory environments, enhancing its ability to deliver innovative treatments worldwide. The company's strategic focus on expanding its market share in Europe and North America is complemented by its efforts to enter new markets in Asia and the Middle East.

- Headquartered in Stockholm, Sweden
- Strong presence in Europe and North America
- Expanding into Asia and the Middle East
- Operations in over 30 countries
- Strategic focus on market share growth in key regions

## Strategy

Sobi's strategic priorities include expanding its portfolio of innovative therapies and increasing its market presence in key regions. The company is focused on strengthening its leadership in haemophilia through new product launches and strategic acquisitions. Sobi aims to enhance its R&D capabilities to accelerate the development of new treatments for rare diseases. The company is also committed to optimizing its go-to-market model and building strong relationships with healthcare professionals and institutions.

- **Expand innovative therapies** (medium-term) — To address unmet medical needs
- **Strengthen haemophilia leadership** (short-term) — To capture market share
- **Enhance R&D capabilities** (long-term) — To accelerate new treatment development

- Expand portfolio of innovative therapies
- Strengthen leadership in haemophilia
- Enhance R&D capabilities for rare diseases
- Optimize go-to-market model
- Build strong relationships with healthcare professionals

## Risks

Sobi faces several risks, including regulatory changes, competitive pressures, and the inherent uncertainties of drug development. The company's reliance on a limited number of key products exposes it to market fluctuations and competitive threats. Additionally, geopolitical risks in regions like China could impact supply chains and market access. The biopharmaceutical industry is also subject to stringent regulatory requirements, which can affect product approvals and market entry.

- **Regulatory changes** [high] — Can delay product approvals
- **Competitive pressures** [medium] — Affects market share and pricing
- **Geopolitical risks** [high] — Impacts supply chains and market access

- Regulatory changes affecting product approvals
- Competitive pressures from other biopharma companies
- Reliance on key products for revenue
- Geopolitical risks impacting supply chains
- Stringent regulatory requirements in the industry

## Accounting

Sobi's financial statements are influenced by several critical accounting matters, including revenue recognition and the impact of milestone payments. The timing of revenue recognition, particularly from royalties and product sales, can lead to fluctuations in quarterly results. Additionally, the accounting for milestone payments related to product approvals and partnerships can significantly affect reported earnings. Sobi must also navigate the complexities of IFRS standards, particularly in relation to deferred tax assets and liabilities.

- **Revenue recognition timing** — high
- **Milestone payments** — medium

- Revenue recognition timing affects quarterly results
- Milestone payments impact reported earnings
- Complexities in IFRS standards for deferred tax
- Fluctuations due to royalty and product sales timing

---

*Last updated: 2026-08-11T04:04:56.489590+00:00*